English

Redeye: Orphazyme - Top-line data in the NPC Phase II/III shows promise

Report this content

Top-line data with arimoclomol showed a promising efficacy at 12 months. We believe the results sets up the company for a potential marketing approval if follow-up data is supportive. The data reduces the clinical risk in the project and we raise our Base Case to DKK 122 (110) per share.

Read more and download the initial research report: http://bit.ly/2Rhu1ez 

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/